Want to see SE:PAX full AI Analyst Report?
Top Page
Paxman AB
(PAX)
Select Model
Select Model
Rating:60Neutral
Price Target:
kr58.00
▲(0.52% Upside)
Action:Reiterated
Date:08/22/26
The score is held back primarily by weakened financial quality—TTM losses and especially negative operating/free cash flow—despite strong revenue growth and a very low-debt balance sheet. Earnings-call commentary is a notable positive, pointing to strong sales momentum, improving adjusted profitability, and a solid cash position, but regulatory timeline risk (De Novo) and elevated costs add uncertainty. Technicals are mildly constructive but not strongly confirmed, and valuation is constrained by negative earnings.
Positive Factors
Revenue Growth and Demand
Strong sales growth and a sizable order book indicate sustained customer adoption and future deployment revenue. Continued demand across markets can support scale, installed-base expansion and greater operating leverage over the next several quarters.
Negative Factors
Negative Cash Generation
Negative operating and free cash flow means growth and investment are not currently funded by the business itself. If this persists, Paxman may need to draw down liquidity or seek external financing, reducing flexibility and increasing execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Demand
Strong sales growth and a sizable order book indicate sustained customer adoption and future deployment revenue. Continued demand across markets can support scale, installed-base expansion and greater operating leverage over the next several quarters.
Read all positive factors
Paxman AB (PAX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.32B
Dividend YieldN/A
Average Volume (3M)25.35K
Price to Earnings (P/E)―
Beta (1Y)0.20
Revenue Growth34.05%
EPS Growth-144.96%
CountrySE
Employees144
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.22
Shares Outstanding23,273,417
10 Day Avg. Volume44,377
30 Day Avg. Volume25,346
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)3.05
Price to Sales (P/S)3.95
P/FCF Ratio-76.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.55
Revenue Forecast (FY)kr414.15M
Paxman AB Business Overview & Revenue Model
Company Description
Paxman AB (publ), along with its subsidiaries, specializes in the creation and worldwide sale of the Paxman scalp cooling system, an innovative solution designed to minimize hair loss in patients undergoing chemotherapy. This system is distributed...
How the Company Makes Money
Paxman primarily makes money by commercializing its scalp cooling therapy platform to oncology infusion centers and hospitals. Its revenue model typically combines (1) sales or placement of scalp cooling systems (capital equipment) to healthcare p...
Paxman AB Earnings Call Summary
Earnings Call Date:Aug 21, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 20, 2026
Earnings Call Sentiment Positive
The call highlights strong commercial momentum: record quarterly sales (+40% YoY), substantial U.S. revenue growth (~+77.5% YoY), large increases in insurance-based billing (110%), improved adjusted margins (~19%), a robust order book (190 systems, 80 in U.S.), and a healthy cash position (SEK 105m). These positives are tempered by a regulatory setback for the neuropathy device (shift to De Novo with an 8–12 month review window), increased operating and CIPN-related costs (OpEx up ~SEK 6m q/q; CIPN costs up ~30%), and a slower near-term U.S. rollout for CIPN. Overall, company fundamentals and commercial traction are strong and appear to outweigh the regulatory and cost challenges, but the De Novo timeline introduces meaningful near-term uncertainty for the new product launch.Positive Updates
Record Group Sales and Strong YoY Growth
Group sales totaled just over SEK 105 million, the first time exceeding SEK 100 million, representing approximately 40% year-on-year growth.
Negative Updates
Regulatory Setback and Timeline Delay for Neuropathy Device
FDA determined there is no suitable predicate, requiring a De Novo submission rather than the planned 510(k). This introduces delay: expected FDA review 8–12 months with commercialization now targeted for Q2 2027 (clearance potentially April–August 2027).
Read all updates
Q2-2026 Updates
Positive
Negative
Record Group Sales and Strong YoY Growth
Group sales totaled just over SEK 105 million, the first time exceeding SEK 100 million, representing approximately 40% year-on-year growth.
Read all positive updates
Company Guidance
Guidance from the call (Q2 FY2026) flagged concrete near‑term targets and key metrics: group sales were just over SEK 105m (≈40% YoY growth) with EBITDA around SEK 14m (Dignitana contributing ~SEK 5.2m), adjusted EBITDA margin ~18.5% (13% including CIPN costs), cash ≈SEK 105m on the balance sheet and ~SEK 5m movement in available cash. Operational datapoints: 56 systems delivered in Q2, 1,326 caps sold via insurance‑based billing (IBBM) as IBBM revenue grew ~110%, order book at 190 systems (80 in the U.S.), and utilization markedly higher under IBBM (8.6 patients/site, 3.4 patients/system) vs self‑pay (3.1/site, 1.6/system). CIPN program: De Novo submission planned this month with an FDA review horizon of ~150 days (overall 8–12 months expected) targeting U.S. commercialization in Q2 2027; build plan includes 50 units already deployed for pilots and up to 150 units with V2 commercial units to start production in Q4 (Oct–Dec). Costs and working capital: OpEx rose ~SEK 6m Q1→Q2 with CIPN/other costs ~SEK 5.6m this quarter (vs SEK 4.3m prior), and management reiterated Europe roll‑out plans (Sept in DE/FR/ES/NL) and a CapEx+consumables commercial model for neuropathy.Paxman AB Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
78
Positive
Cash Flow
42
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 365.91M | 313.35M | 253.01M | 210.12M | 156.75M | 96.20M |
| Gross Profit | 116.80M | 208.81M | 175.42M | 146.42M | 101.44M | 64.52M |
| EBITDA | 37.95M | 28.46M | 49.73M | 31.23M | 16.18M | 1.25M |
| Net Income | -5.05M | -16.71M | 40.20M | 8.33M | -10.32M | -12.78M |
Balance Sheet | ||||||
| Total Assets | 488.20M | 479.11M | 227.23M | 167.12M | 173.96M | 166.34M |
| Cash, Cash Equivalents and Short-Term Investments | 105.64M | 120.83M | 40.31M | 24.98M | 38.09M | 72.27M |
| Total Debt | 12.37M | 13.01M | 14.29M | 13.57M | 16.98M | 17.15M |
| Total Liabilities | 71.29M | 73.95M | 63.24M | 44.51M | 59.76M | 40.59M |
| Stockholders Equity | 416.91M | 405.16M | 163.99M | 122.62M | 114.20M | 125.75M |
Cash Flow | ||||||
| Free Cash Flow | -24.16M | -16.09M | 15.99M | -9.70M | -33.01M | -27.94M |
| Operating Cash Flow | -5.83M | 7.39M | 39.10M | 15.63M | 2.69M | -4.14M |
| Investing Cash Flow | -32.90M | -33.51M | -24.50M | -25.33M | -36.69M | -24.45M |
| Financing Cash Flow | -9.94M | 108.83M | 721.00K | -3.41M | -169.00K | 97.28M |
Paxman AB Technical Analysis
Positive
57.70
Price Trends
49.26
Positive
50.02
Positive
50.66
Positive
Market Momentum
2.63
Negative
68.31
Neutral
74.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PAX, the sentiment is Positive. The current price of 57.7 is above the 20-day moving average (MA) of 51.22, above the 50-day MA of 49.26, and above the 200-day MA of 50.66, indicating a bullish trend. The MACD of 2.63 indicates Negative momentum. The RSI at 68.31 is Neutral, neither overbought nor oversold. The STOCH value of 74.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:PAX.
Paxman AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | kr8.28B | 94.02 | 4.13% | ― | 8.79% | -20.48% | |
60 Neutral | kr1.32B | -265.35 | -1.22% | ― | 34.05% | -144.96% | |
54 Neutral | kr1.14B | -32.12 | -3.99% | ― | -0.34% | 29.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr578.22M | -67.92 | -2.84% | ― | -13.72% | 52.47% | |
46 Neutral | kr363.68M | -7.74 | -22.23% | ― | 6.49% | 25.03% | |
44 Neutral | kr555.76M | -4.65 | -37.43% | ― | 27.40% | 26.07% |
* Healthcare Sector Average
SE:PAX
Paxman AB
57.90
-20.10
-25.77%
SE:SEZI
Senzime AB
3.30
-3.16
-48.92%
SE:XVIVO
Xvivo Perfusion AB
264.20
94.60
55.78%
SE:BACTI.B
Bactiguard Holding AB
16.30
-9.80
-37.55%
SE:BRAIN
BrainCool AB
0.90
-0.02
-1.64%
SE:SEDANA
Sedana Medical AB
11.48
-2.08
-15.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.